Purpose: To report the clinical course of 6 patients with refractory neurotrophic corneal ulcers that were treated with topical insulin drops.
N eurotrophic keratopathy is a degenerative disease of the corneal epithelium secondary to impaired corneal innervation by the trigeminal nerve. Standard treatment involves aggressive lubrication of the corneal surface, therapeutic contact lenses, amniotic membrane grafts, and tarsorrhaphy. Refractory neurotrophic corneal ulcers occur when the treatment response is incomplete and are potentially blinding. Insulin is a widely available, relatively safe, and familiar medication that has been shown to improve corneal epithelial healing in vitro and in diabetic animal models. However, clinical experience with topical insulin in patients with nonhealing corneal wounds is minimal. The purpose of this study is to present 6 patients with refractory neurotrophic corneal ulcers that were treated with topical insulin.
METHODS AND MATERIALS
A retrospective chart review of 6 patients at the University of Wisconsin was conducted with approval from the university's Institutional Review Board. All patients were prescribed insulin drops as compassionate use for the treatment of neurotrophic corneal ulcers after standard treatment had failed. The risks, benefits, and alternatives of the treatment were discussed with all patients and/or their parents, and they verbally consented to the off-label use of insulin.
Unless otherwise noted, the drops were prepared by injecting regular insulin into a new bottle of artificial tears with a polyethylene glycol and propylene glycol base at a concentration of 1 unit per milliliter. Drops were prepared by pharmacy, the patients' providers, or the patients themselves with detailed written instructions. This was done with sterile technique. The drops were refrigerated and used up to 1 month after preparation.
RESULTS

Case 1
A 2-year-old girl with a history of an excised teratoma involving the left orbit resulting in proptosis and lagophthalmos presented with a large corneal ulcer of the left eye. The ulcer measured 7 · 4 mm on presentation (Fig. 1A) . Corneal sensation was absent in the affected eye. After 5 months of aggressive treatment, including permanent lateral tarsorrhaphy and inferior rectus recession to encourage a Bell phenomenon, the ulcer remained. The patient was administered topical insulin drops 3 times daily. After 14 days of treatment, the ulcer had healed completely (Fig. 1B) . The insulin was tapered to once daily. At 18-month follow-up, the corneal epithelium remained intact.
Case 2
A 2-year-old boy with a history of aniridia and surgically controlled bilateral congenital glaucoma presented with a corneal epithelial defect measuring 5 · 6.5 mm in the left eye. Formal corneal sensation testing was not performed; however, the patient's cornea was presumed to be hypesthetic as he was asymptomatic. The patient was treated with antibiotic ointment and amniotic membrane grafting twice. After 5 months with a persistent epithelial defect, insulin drops were started 3 times daily. After 13 days of treatment, the corneal epithelium had healed completely and the drop was tapered to twice daily. The patient has had no recurrent epithelial defect 1 year since treatment initiation.
Case 3
A 24-year-old woman with a history of herpes zoster keratoconjunctivitis and neurotrophic keratopathy in the left eye presented with a persistent epithelial defect and mild ulceration. She developed the defect, which measured 3 · 2 mm, despite daily use of a scleral contact lens (Fig. 1C) . Insulin drops were started twice daily and at 2-week followup, the defect improved to 1 · 1 mm. After another 2 weeks, the epithelial defect had resolved, with some residual epithelial irregularity (Fig. 1D) . The patient used the insulin drops for a total of 25 days; they were discontinued and follow-up was transferred when she moved out of state.
Case 4
A 47-year-old woman with a history of neurotrophic keratopathy in both eyes secondary to cranial nerve injury and a large corneal scar in the left eye from a previous ulcer presented with a near descemetocele in the central cornea of the left eye. The area of thinning measured 1.5 · 2.5 mm on presentation (Fig. 1E) . The patient had previously had a surgical tarsorrhaphy in the left eye. She was diabetic on lispro insulin and was administered insulin drops (2 units of lispro in 10 mL of artificial tears) 2 to 3 times daily. After 7 days of treatment, the ulcer had healed completely with thickened epithelium over the previous descemetocele (Fig.  1F) . The drops were used for a total of 3 weeks and were discontinued secondary to patient preference.
Case 5
A 71-year-old woman presented with a nonhealing, asymptomatic 4 · 4 mm epithelial defect after vitrectomy. She was treated with lubrication, bandage contact lens, and amniotic membrane graft with minimal improvement over the course of 4 months. Insulin drops were started twice, and after 14 days of treatment, the epithelial defect had resolved. The insulin drops were tapered to once daily, and the patient selfdiscontinued them after several months. At 1-year follow-up, the epithelium remained intact with no recurrent defect.
Case 6
A 73-year-old woman with a history of herpes zoster neurotrophic keratopathy presented with a nonhealing epithelial defect of the left eye. She was treated with amniotic membrane 3 times, temporary tarsorrhaphy, and chronic topical steroid therapy. After 2 months, the defect persisted at 1.5 · 2.5 mm, and the patient was administered insulin drops 3 times daily. After 8 days of treatment, the epithelial defect had resolved. Four months after initial presentation, the patient developed a large infectious ulcer and crystalline keratopathy. Administration of insulin drops was continued during this time, with the epithelial defect slowly improving. Three months after development of crystalline keratopathy, the patient had a flare of zoster keratitis and the insulin drops were discontinued.
DISCUSSION
We present 6 patients who developed neurotrophic corneal ulcers or epithelial defects that were refractory to a range of standard medical and surgical treatments. Addition of topical insulin resulted in rapid and complete corneal reepithelialization ranging from 7 to 25 days after initiation of treatment. One patient developed crystalline keratopathy while on treatment, although this was likely secondary to chronic topical steroid use. No other local or systemic side FIGURE 1. Three patients treated with topical insulin. A 2-year-old girl with proptosis and lagophthalmos from an orbital teratoma presented with a neurotrophic corneal ulcer refractory to lubrication and permanent lateral tarsorrhaphy (A). Insulin eye drops were initiated with resolution of the ulcer after 14 days (B). A 24-year-old woman with neurotrophic keratopathy secondary to herpes zoster keratitis presented with a corneal ulcer refractory to lubrication and use of a scleral contact lens (C). Insulin drops were initiated with resolution of the ulcer after 25 days (D). A 47-year-old woman with neurotrophic keratopathy secondary to cranial nerve injury presented with near-descemetocele in the central coreffects were noted, including changes in corneal vascularization or opacity.
Topical insulin has been found to improve healing of decubitus ulcers 1 and experimentally induced superficial skin wounds in diabetic and nondiabetic individuals. 2 The effect of topical insulin on corneal wound healing has been well studied in rodent models. Notably, in diabetic rats, topical insulin improves corneal sensation and improves wound healing after corneal abrasions. 3 Experience with insulin in corneal wound healing in humans is limited to 2 case series. A 1945 study reported improved healing of corneal ulcers after systemic administration of insulin. 4 A 2013 retrospective study looked at 5 patients who developed corneal epithelial defects during vitreoretinal surgery who were treated with topical insulin drops and reported faster reepithelialization compared with 10 patients who were treated with lubrication. 5 There have been no previous studies of topical insulin use in patients with neurotrophic corneal defects.
The mechanism of insulin in promoting cornea wound healing in our patients remains speculative, but data suggest that restoration of corneal nerves and/or improved epithelial cell migration may play key roles. In diabetic mice, topical insulin has been shown to slow the loss of subbasal plexus corneal nerves. 6 Furthermore, the addition of insulin promoted cell migration and closure of artificial wounds in cultured sheets of corneal epithelial cells in an in vitro model of corneal epithelial wound healing. 7 Insulin-like growth factor-1 (IGF-1) has been shown to be an important modulator of corneal wound healing. In several preclinical studies, IGF-1 was shown to act synergistically with substance-P to promote corneal epithelium wound healing. 8 In 2 case series, patients with neurotrophic corneal epithelial defects treated with a topical combination of substance P-derived peptides and either IGF-1 or IGF-1-derived peptides underwent complete epithelial resurfacing within 4 weeks, at response rates of 89% 9 and 73%. 10 Topical insulin may be a simple and effective treatment for refractory neurotrophic corneal ulcers. Our case series is limited by the heterogeneity in the patient presentations, differences in treatment frequency and duration, and lack of a comparative control. Further study is needed to determine the clinical efficacy and side effect profile of topical insulin in corneal wound healing.
